An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of 1.5 mg/day dose of
paliperidone Extended Release (ER) as compared with placebo when used to treat patients with
schizophrenia.
Phase:
Phase 4
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.